Mayo Clinic recruiting for phase 2 stem cell clinical trials for treatment of SCI

Rochester, Minnesota’s Mayo Clinic Phase 2 clinical trials, that involve the use of stem cells extracted from the body’s stomach fat and injected into the spinal cord, are now recruiting candidates. In this phase, researchers will investigate the safety and potential therapeutic effects of autologous, culture-expanded, adipose derived mesenchymal stem cell intrathecal injections in the treatment of spinal cord injury, including the side effects, optimal dosages and risks/benefits. Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.

There are multiple eligibility requirements, including being 18 years or older, SCI must be traumatic, blunt/non-penetrating (no gunshot injuries) in nature and not degenerative, and an AIS grade of A or B. You can learn more about this trial and how to enroll HERE,